Resources for healthcare providers.
Review prescribing concepts, trial data, and support materials for adults with Nocturnal Continuity Dysregulation.
Clinical positioning for adults with moderate to severe NCD
SLUMBARA is indicated for the treatment of Nocturnal Continuity Dysregulation in adults with recurrent sleep-fragmentation burden, prolonged return-to-sleep latency, and associated next-day functional impairment.
total adults across the LANTERN program.
achieved composite continuity response by Week 12.
pooled mean reduction in cumulative nocturnal wake time.
mean Morning Cognitive Sealing Index improvement vs 3.6 with placebo.
Patient selection and dosing
- Consider adults with confirmed continuity-collapse phenotype rather than isolated sleep-onset complaints
- Recommended starting dose: 18 mg nightly; lower starting dose may be appropriate in older adults or hepatic impairment
- Do not combine with orexin antagonists or concurrent hypnotic therapy unless clinically justified and closely monitored
- Reassess morning tolerability within 7–14 days of initiation
Suggested workup
Sleep history focused on post-onset awakenings, time-to-return-to-sleep, overnight trigger patterns, morning function, and medication co-exposures. Optional continuity diary can help identify fragmentation burden.
Pooled LANTERN endpoint summary
| Endpoint | SLUMBARA | Placebo / comparator | P value |
|---|---|---|---|
| Cumulative nocturnal wake time | -58 min | -19 min | <0.001 |
| Median return-to-sleep latency | -27 min | -9 min | <0.001 |
| Morning Cognitive Sealing Index | -9.2 points | -3.6 points | 0.002 |
| Patient Global Continuity Impression responder rate | 64% | 29% | <0.001 |
Support for your practice
- Sample prior authorization checklist
- Night Access Card enrollment support
- Patient continuity diary starter kit
- NCD education materials for office use
Representative support
Contact your Elara representative for coverage support tools, formulary updates, and educational materials about identifying the continuity-collapse phenotype.
About this experience
This website is a satirical brand experience created for entertainment and storytelling purposes. SLUMBARA, Elara Therapeutics, and all related conditions, trial programs, claims, and product information presented here are fictional.